Rilzabrutinib is a Small Molecule owned by Principia Biopharma, and is involved in 17 clinical trials, of which 9 were completed, 7 are ongoing, and 1 is planned.
Rilzabrutinib (PRN-1008) is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a non-receptor tyrosine kinase, that promotes B lymphocyte development, differentiation and signaling. Activation of Btk triggers the generation of calcium mobilization and transcriptional regulation and production of pro-inflammatory cytokines. The drug candidate by inhibiting BTK activity, reduces the pathogenic autoantibody production of B cells along with the pro-inflammatory cytokines resulting in immune suppression.
The revenue for Rilzabrutinib is expected to reach a total of $2.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rilzabrutinib NPV Report.
Rilzabrutinib (PRN-1008) is under development for the treatment of autoimmune hemolytic anemia, immune thrombocytopenic purpura, asthma, Chronic spontaneous urticaria, atopic dermatitis and IgG4-related disease. The drug candidate is a small molecule administered orally. The drug candidate targets Bruton's tyrosine kinase (BTK) enzyme. It is based on Tailored covalency technology platform. It was also under development for rheumatoid arthritis, systemic lupus erythematosus (SLE) and inflammatory bowel disease.
Rilzabrutinib was under development for the treatment of pemphigus foliaceus, newly diagnosed or relapsing pemphigus vulgaris,
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.
Quick View – Rilzabrutinib
|Highest Development Stage|